Allosteric Modulation of the Muscarinic M4 Receptor As an Approach to Treating Schizophrenia

Total Page:16

File Type:pdf, Size:1020Kb

Allosteric Modulation of the Muscarinic M4 Receptor As an Approach to Treating Schizophrenia Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia W. Y. Chan*, D. L. McKinzie†, S. Bose*, S. N. Mitchell*, J. M. Witkin†, R. C. Thompson‡, A. Christopoulos§, S. Lazareno¶, N. J. M. Birdsallʈ, F. P. Bymaster†, and C. C. Felder*†** *Neuroscience Discovery Research, Lilly Research Centre, Surrey GU20 6PH, United Kingdom; †Neuroscience Division and ‡Discovery Chemistry and Research Technologies, Lilly Corporate Center, Indianapolis 46285; §Department of Pharmacology, Drug Discovery Biology Laboratory, Monash University, Melbourne, Victoria 3010, Australia; ¶MRC Technology, Mill Hill, London NW7 1AD, United Kingdom; and ʈDivision of Physical Biochemistry, Medical Research Council National Institute for Medical Research, Mill Hill, London NW7 1AA, United Kingdom Edited by L. L. Iversen, University of Oxford, Oxford, United Kingdom, and approved April 17, 2008 (received for review January 23, 2008) Current antipsychotics provide symptomatic relief for patients types, in the pathophysiology of schizophrenia (5, 6). Muscarinic suffering from schizophrenia and related psychoses; however, receptors are genetically linked to schizophrenia and cognitive their effectiveness is variable and many patients discontinue treat- deficits (7, 8). Pharmacologically, relatively non-selective mus- ment due to side effects. Although the etiology of schizophrenia is carinic antagonists exacerbate, whereas agonists ameliorate, still unclear, a leading hypothesis implicates an imbalanced dopa- cognitive deficits and psychotic behaviors in animal models and minergic system. Muscarinic acetylcholine (ACh) receptors regulate in patients suffering from Alzheimer’s disease and schizophrenia dopamine levels in key areas of the brain involved in psychosis, (9–12). In particular, the M1/M4 preferring partial agonist, with the M4 subtype emerging as a key regulator of dopaminergic xanomeline, was found to be efficacious in animal models hyperactivity. Unfortunately, no selective small molecule tools predictive of antipsychotic behaviors through modulation of exist to provide pharmacological validation of this hypothesis. both dopamine and glutamate transmission (13). In exploratory Here, we describe the discovery of a small molecule modulator, clinical trials, xanomeline reduced psychotic behaviors and improved cognitive measures in Alzheimer’s patients (9), and LY2033298, that is highly selective for human M4 receptors by virtue of targeting an allosteric site on this receptor. Pharmaco- significantly improved positive, negative, and cognitive symp- toms in a small schizophrenia trial (12). Unfortunately, lack of logical assays confirmed the selectivity of LY2033298 for the M 4 receptor subtype selectivity led to undesirable side-effects (gas- receptor and revealed the highest degree of positive allosteric trointestinal disturbances, blood pressure dysregulation) that enhancement of ACh potency thus far identified. Radioligand rendered xanomeline as an unsuitable candidate for further binding assays also show this compound to directly potentiate clinical development (14). agonist binding while having minimal effects on antagonist bind- M receptors are most highly expressed in brain regions rich 432 4 ing. Mutational analysis identified a key amino acid (D )inthe in dopamine and dopamine receptors (15, 16). Experiments with third extracellular loop of the human M receptor to be critical for 4 muscarinic knock out mice have implicated the M4 receptor selectivity and agonist potentiation by LY2033298. Importantly, subtype in regulating dopaminergic neurons involved in move- LY2033298 was active in animal models predictive of clinical ment control and cognition (17, 18); therefore, we reasoned that antipsychotic drug efficacy indicating its potential use as a first- a highly selective M4 muscarinic receptor activator may represent in-class, selective, allosteric muscarinic antipsychotic agent. a useful candidate for the development of muscarinic-based antipsychotic agents. Unfortunately, attempts at discovering cholinergic ͉ GPCR ͉ cooperativity selective small molecule ligands for the five muscarinic receptor subtypes have largely been unsuccessful when targeted at the chizophrenia is a complex disease presenting a broad spec- receptors’ orthosteric site, i.e., the binding site for the endoge- Strum of endophenotypes that can be generalized to symp- nous agonist ACh, which is highly conserved across all five toms in three major domains: positive (hallucinations, hearing of muscarinic subtypes (19). This has been particularly true for the voices, delusions and disorganized thinking), negative (anhedo- ACh-mimetics, such as xanomeline, sabcomeline, and melame- line (20). However, it is also known that muscarinic receptors nia, flat affect), and cognitive (attention and working memory possess allosteric binding sites that have the potential to show deficits). The etiological basis for the disease is believed to derive greater sequence divergence across subtypes and, hence, may predominantly from dysregulation of dopamine and glutamate provide an alternative means of attaining receptor subtype neurotransmission pathways in mesocortical and mesolimbic selectivity (21, 22). Allosteric modulators also offer the addi- brain areas (1–3). Atypical antipsychotics are the current front- tional potential of maintaining both spatial and temporal neu- line treatment for schizophrenia, ameliorating the positive symp- rotransmission through modulation of physiologically relevant toms in approximately half of the treated patient population with receptor-mediated neural regulation, as opposed to direct (con- little efficacy at the negative and cognitive symptoms. Most atypical antipsychotics are broad spectrum G protein-coupled receptor (GPCR) antagonists, and their therapeutic action is Author contributions: W.Y.C., D.L.M., J.M.W., R.C.T., A.C., S.L., N.J.M.B., F.P.B., and C.C.F. designed research; W.Y.C., D.L.M., S.B., S.N.M., J.M.W., R.C.T., S.L., N.J.M.B., F.P.B., and mediated primarily through inhibition of dopamine D2,D3 and C.C.F. performed research; R.C.T. contributed new reagents/analytic tools; W.Y.C., S.B., D4, and serotonin 5HT2A, receptors (4). Their complex phar- S.N.M., A.C., S.L., N.J.M.B., and C.C.F. analyzed data; and W.Y.C., S.B., S.N.M., A.C., S.L., macology, however, leads to significant undesirable side effects, N.J.M.B., and C.C.F. wrote the paper. including movement disorders and weight gain. Therefore, de- Conflict of interest statement: W.Y.C., D.L.M., S.B., S.N.M., J.M.W., R.C.T., F.P.B., and C.C.F. veloping antipsychotics through an alternative mechanism may are or were employed by Eli Lilly & Co. provide better total symptom control and reduced side effects. This article is a PNAS Direct Submission. The family of five muscarinic acetylcholine (ACh) receptors Freely available online through the PNAS open access option. plays a prominent role in regulating neurotransmission in the **To whom correspondence should be addressed at: Eli Lilly & Co. Research Laboratories, CNS and may provide a mechanism for antipsychotic drug Lilly Corporate Center, Indianapolis, IN 46285. E-mail: [email protected]. discovery. Studies using muscarinic receptor knock out mice This article contains supporting information online at www.pnas.org/cgi/content/full/ have provided valuable insight into the potential role of these 0800567105/DCSupplemental. receptors, especially the muscarinic receptor M1 and M4 sub- © 2008 by The National Academy of Sciences of the USA 10978–10983 ͉ PNAS ͉ August 5, 2008 ͉ vol. 105 ͉ no. 31 www.pnas.org͞cgi͞doi͞10.1073͞pnas.0800567105 Downloaded by guest on September 25, 2021 activation, using cell lines stably expressing the hM1–M5 recep- A tors coupled to intrinsic or engineered calcium signaling path- ways. No agonist activity at any muscarinic receptor subtype was detected when LY2033298 was applied alone. However, upon addition of a submaximal concentration of ACh, an elevated calcium response was readily detected in the hM4 cell lines relative to the effect of the same concentration of ACh in the absence of LY2033298. Subsequent assays constructed complete concentration-response curves to ACh in the presence of in- creasing concentrations of LY2033298. As shown in Fig. 1A, these experiments revealed a prototypical characteristic of pos- itive allosteric interactions: a robust potentiation of agonist potency that reached a limit at the highest concentrations of allosteric modulator above which no further effect was obtained (24). Application of an allosteric ternary complex model to the data yielded KB ϭ 200 Ϯ 40 nM for LY2033298 at the allosteric site on the unoccupied hM4 receptor, and ␣ ϭ 35 Ϯ 4 for the degree of allosteric enhancement when both orthosteric and allosteric sites are occupied; to our knowledge, this is the highest degree of positive cooperativity reported for any allosteric modulator of a muscarinic receptor. In addition, these experi- ments also revealed the high selectivity of LY2033298 for the hM4 receptor, because there was no effect at hM1/3/5 receptors at B any concentration of modulator and a very small allosteric potentiation at the closest homolog, hM2 (KB ϭ 1.0 Ϯ 0.3 ␮M; ␣ ϭ 3.7 Ϯ 0.5). The positive allosteric effect of LY2033298 at the hM4 receptor was not unique to ACh, because it also selectively potentiated other full and partial orthosteric agonists, such as NEUROSCIENCE carbachol, oxotremorine-M, and McN-A343 (data not shown). To confirm that the allosteric effect detected
Recommended publications
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Wo 2007/128674 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 15 November 2007 (15.11.2007) PCT WO 2007/128674 A2 (51) International Patent Classification: Houtenlaan 36, NL-1381 CP Weesp (NL). KRUSE, Cor- A61K 31/00 (2006.01) A61K 31/551 (2006.01) nelis G. [NL/NL]; c/o SOLVAY PHARMACEUTICALS A61K 31/439 (2006.01) A61P 25/18 (2006.01) B.V., IPSI Department, CJ. Van Houtenlaan 36, NL-1381 A61K 31/4439 (2006.01) CP Weesp (NL). (21) International Application Number: (74) Agent: VERHAGE, Marinus; Octrooibureau Zoan B.V., PCT/EP2007/053934 NL-1380 AC Weesp (NL). (22) International Filing Date: 23 April 2007 (23.04.2007) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, (25) Filing Language: English CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, (26) Publication Language: English IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, MG, MK, MN, MW, MX, MY, (30) Priority Data: MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, 061 13476.3 4 May 2006 (04.05.2006) EP RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, 60/797,355 4 May 2006 (04.05.2006) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (71) Applicant (for all designated States except US): SOLVAY (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS B.V.
    [Show full text]
  • Alzheimer's Disease Clinical Trials
    Clinical Trial Perspective 5 Clinical Trial Perspective Alzheimer’s disease clinical trials: past failures and future opportunities Clin. Invest. (Lond.) Over a decade has elapsed since the US FDA has approved a medication for Alzheimer’s Roy Yaari*,1,2 & Ann Hake1,2 disease (AD) despite clinical trials of numerous agents over a wide array of mechanisms 1Eli Lilly & Company, Lilly Corporate including neurotransmitter modulation and disease modifying therapy targeting Center, Indianapolis, IN 46285, USA 2Indiana University School of Medicine, amyloid and tau. The failures of clinical trials in AD may be due to inadequate Department of Neurology, Indianapolis, understanding of mechanisms of action and/or poor target engagement; however, IN 46202, USA other factors could include inadequate study design, stage of AD along the continuum *Author for correspondence: studied, inclusion of participants without Alzheimer’s pathology into clinical trials Tel.: +1 317 651 6163 and limited power of endpoint measures. Future studies will need to carefully assess [email protected] these possible shortcomings in design of upcoming trials, especially as the field moves toward studies of disease modifying agents (as opposed to symptomatic treatment) of AD and to patients that are very early in the disease spectrum. Keywords: Alzheimer’s disease • Alzheimer’s disease biomarkers • amyloid • clinical trials • preclinical Alzheimer’s disease • tau US FDA approved medications continue to provide significant, but modest More than three decades ago, the choliner- symptomatic benefit[5–7] . gic hypothesis proposed that degeneration The compound memantine introduced a of cholinergic neurons in the basal fore- second mechanism for symptomatic treat- brain and the associated loss of cholinergic ment of AD into clinical practice.
    [Show full text]
  • The Profile of Sabcomeline (SB-202026), a Functionally Selective M1 Receptor Partial Agonist, in the Marmoset
    British Journal of Pharmacology (1998) 124, 409 ± 415 1998 Stockton Press All rights reserved 0007 ± 1188/98 $12.00 http://www.stockton-press.co.uk/bjp The pro®le of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset 1M.H. Harries, N.A. Samson, J. Cilia & A.J. Hunter Neurosciences Research, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW 71 1 Sabcomeline (SB-202026, 0.03 mg kg , p.o.), a potent and functionally selective M1 receptor partial agonist, caused a statistically signi®cant improvement in the performance of a visual object discrimination task by marmosets. No such improvement was seen after RS86 (0.1 mg kg71, p.o.). 2 Initial learning, which only required an association of object with reward and an appropriate response to be made, was not signi®cantly aected. Reversal learning, which required both the extinction of the previously learned response and the acquisition of a new response strategy, was signi®cantly improved after administration of sabcomeline (0.03 mg kg71, p.o.). 3 Sabcomeline (0.03 and 0.1 mg kg71, p.o.) had no signi®cant eect on mean blood pressure measured for 2 h after administration in the conscious marmoset. 4 Sabcomeline (0.03 mg kg71, p.o.) caused none of the overt eects such as emesis or behaviours often seen after the administration of muscarinic agonists, e.g. face rubbing and licking. 5 This is the ®rst study to demonstrate cognitive enhancement by a functionally selective M1 receptor partial agonist in a normal (i.e.
    [Show full text]
  • 30Th Annual Meeting of Society for Neuroscience. New Drugs Affecting the Central Nervous System New Orleans, Louisiana, USA November 4–9, 2000
    CNS Drug Reviews Vol. 7, No. 2, pp. 241–248 © 2001 Neva Press, Branford, Connecticut MEETING REPORT 30th Annual Meeting of Society for Neuroscience. New Drugs Affecting the Central Nervous System New Orleans, Louisiana, USA November 4–9, 2000 Alexander Scriabine Yale University School of Medicine, New Haven, CT, USA The 30th meeting of the Society for Neuroscience was held on November 4–9 in New Orleans, LA, USA. The meeting was attended by ~25,000 scientists and exhibitors. There were 874 slide or poster sessions, symposia or special lectures. Each session contained 10 to 20 presentations. This report covers only selected posters on new drugs affecting the central nervous system. NEUROPROTECTIVE DRUGS M. Cheng et al. (Centaur Pharmaceuticals, Inc., Sunnyvale, CA, USA) presented NXY-50, a novel free radical trapping agent, that was found to reduce infarct volume in rats with permanent focal ischemia induced by occlusion of middle cerebral artery (MCAO). The drug (30 or 60 mg/kg) was administered at 5 min after MCAO by i.v. bolus followed by infusion for 24 h (same dose per hour). The animals were sacrificed at 24 h after MCAO. The infarct volumes were estimated by histochemical staining. At 60 mg/kg the effect of the drug was statistically significant. J. Peeling et al. (Univ. of Mannitoba, Winnipeg, Canada, Memorial Univ., St. John’s, Newfoundland, Canada and AstraZeneca, Loughborough, UK and Södertalje, Sweden) studied NXY-059 in a rat model of hemorrhagic stroke. Intracerebral hemorrhage (ICH) was induced in rats by infusion of collagenase into SO Na 3 the right caudate nucleus.
    [Show full text]
  • Alzheimer Syllabus
    Update on Alzheimer’s Disease June, 2006 Stephen S. Flitman, MD, Medical Director 21 st Century Neurology 3100 North Third Ave Suite 100, Phoenix, Arizona (602) 265-6500 www.neurozone.org Alzheimer’s Disease (AD), first described by Dr. Alois Alzheimer in 1907, is a disorder that 10 million Americans are thought to have, but less than 40% are diagnosed or receiving treatment now. It is very common, affecting people ages 40-90 with 2-4% prevalence at ages 65- 75 and increasing in subsequent decades. After heart disease, cancer, and stroke it is the fourth leading cause of death in the US. AD is a disorder of the gray matter of the cerebral cortex. It is characterized clinically by gradually progressive dementia and pathologically by extraneuronal plaques and intraneuronal neurofibrillary tangles by light microscopy. AD progresses anatomically via the connections made by affected neurons. It starts in the entorhinal cortex and then spreads to the hippocampus, basal nuclei, and then to the neocortex. It spares primary motor and sensory cortices, preferentially attacking association areas in the frontal, parietal, and temporal lobes. Affected regions have neurochemical deficits of acetylcholine, glutamate, and serotonin. The degree of dementia correlates with the decline in these neurotransmitters in biopsy or autopsy tissue. While short-term memory deficits predominate early in the progressive dementias, the term dementia is reserved for a clinical syndrome of memory disorder plus at least one other cognitive realm: language, motor or procedural memory (praxis), spatial function, and executive function (decision-making, planning, overall control of behavior). As an etiology for dementia, AD accounts for about two-thirds of cases, with metabolic causes and Lewy body disease making up the lion’s share of the remaining third.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Clinical Trials and Late-Stage Drug Development in Alzheimer's Disease: an Appraisal from 1984 to 2014
    WellBeing International WBI Studies Repository 3-2014 Clinical trials and late-stage drug development in Alzheimer’s disease: An appraisal from 1984 to 2014 L. S. Schneider University of Southern California F. Mangialasche Karolinska Institutet and Stockholm University S. Andreasen Karolinska University Hospital H. Feldman University of British Columbia E. Giacobini University of Geneva See next page for additional authors Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/humctri Part of the Bioethics and Medical Ethics Commons, Clinical Trials Commons, and the Laboratory and Basic Science Research Commons Recommended Citation Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., ... & Kivipelto, M. (2014). Clinical trials and late‐stage drug development for A lzheimer's disease: an appraisal from 1984 to 2014. Journal of internal medicine, 275(3), 251-283. This material is brought to you for free and open access by WellBeing International. It has been accepted for inclusion by an authorized administrator of the WBI Studies Repository. For more information, please contact [email protected]. Authors L. S. Schneider, F. Mangialasche, S. Andreasen, H. Feldman, E. Giacobini, R. Jones, V. Mantua, P. Mecocci, L. Pani, B. Winblad, and M. Kivipelto This conference proceeding is available at WBI Studies Repository: https://www.wellbeingintlstudiesrepository.org/ humctri/3 Key Symposium Click here for more articles from the symposium doi: 10.1111/joim.12191 Watch Guest Editor Professor Mila Kivipelto talk about the 9th Key Symposium: Updating Alzheimer’s Disease Diagnosis here. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014 L.
    [Show full text]
  • Characterization of a CNS Penetrant, Selective M1 Muscarinic Receptor Agonist, 77-LH-28-1
    British Journal of Pharmacology (2008) 154, 1104–1115 & 2008 Nature Publishing Group All rights reserved 0007– 1188/08 $30.00 www.brjpharmacol.org RESEARCH PAPER Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1 CJ Langmead1, NE Austin1, CL Branch1, JT Brown2, KA Buchanan3, CH Davies1, IT Forbes1, VAH Fry1, JJ Hagan1, HJ Herdon1, GA Jones1, R Jeggo4, JNC Kew1, A Mazzali5, R Melarange1, N Patel1, J Pardoe1, AD Randall2, C Roberts1, A Roopun6, KR Starr1, A Teriakidis2, MD Wood1, M Whittington6,ZWu7 and J Watson1 1Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, UK; 2Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, UK; 3MRC Centre for Synaptic Plasticity, Department of Anatomy, University of Bristol School of Medical Sciences, University Walk, Bristol, UK; 4NeuroSolutions Ltd., Coventry, UK; 5Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Verona, Italy; 6School of Neurology, Neurobiology and Psychiatry, Newcastle University, Newcastle upon Tyne, UK and 7Molecular Discovery Research, GlaxoSmithKline, Upper Providence, Collegeville, PA, USA Background and purpose: M1 muscarinic ACh receptors (mAChRs) represent an attractive drug target for the treatment of cognitive deficits associated with diseases such as Alzheimer’s disease and schizophrenia. However, the discovery of subtype- selective mAChR agonists has been hampered by the high degree of conservation of the orthosteric ACh-binding site among mAChR subtypes. The advent of functional screening assays has enabled the identification of agonists such as AC-42 (4-n- butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine), which bind to an allosteric site and selectively activate the M1 mAChR subtype.
    [Show full text]
  • A Straightforward Route to Enantiopure Pyrrolizidines And
    Molecules 2001, 6, 142-193 molecules ISSN 1420-3049 http://www.mdpi.org Review Muscarinic Receptor Agonists and Antagonists Kenneth J. Broadley1 and David R. Kelly2,* 1Division of Pharmacology, Welsh School of Pharmacy and 2Department of Chemistry, Cardiff University, Cathays Park, Cardiff, CF10 3TB, UK *To whom correspondence should be addressed; e-mail: [email protected] Received: 2 August 2000; in revised form 16 January 2001 / Accepted: 16 January 2001 / Published: 28 February 2001 Abstract: A comprehensive review of pharmacological and medical aspects of the muscarinic class of acetylcholine agonists and antagonists is presented. The therapeutic benefits of achieving receptor subtype selectivity are outlined and applications in the treatment of Alzheimer’s disease are discussed. A selection of chemical routes are described, which illustrate contemporary methodology for the synthesis of chiral medicinal compounds (asymmetric synthesis, chiral pool, enzymes). Routes to bicyclic intrannular amines and intramolecular Diels-Alder reactions are highlighted. Keywords: Alzheimer’s disease, nicotine, acetylcholine, arecoline, himbacine, tacrine, cyclostelletamines, intramolecular Diels-Alder reaction, indole alkaloids Contents 1 The Pharmacology of Muscarinic Receptors 1.1 Introduction 1.2 Muscarinic receptor subtypes Molecules 2001, 6 143 2 Pharmacological Effects of Agonists and Therapeutic Applications 2.1 Cardiovascular system 2.2 Gastointestinal tract 2.3 Other smooth muscle 2.4 Glandular secretions 2.5 The eye 2.6 Central nervous
    [Show full text]
  • Botulinum Toxin
    Botulinum toxin From Wikipedia, the free encyclopedia Jump to: navigation, search Botulinum toxin Clinical data Pregnancy ? cat. Legal status Rx-Only (US) Routes IM (approved),SC, intradermal, into glands Identifiers CAS number 93384-43-1 = ATC code M03AX01 PubChem CID 5485225 DrugBank DB00042 Chemical data Formula C6760H10447N1743O2010S32 Mol. mass 149.322,3223 kDa (what is this?) (verify) Bontoxilysin Identifiers EC number 3.4.24.69 Databases IntEnz IntEnz view BRENDA BRENDA entry ExPASy NiceZyme view KEGG KEGG entry MetaCyc metabolic pathway PRIAM profile PDB structures RCSB PDB PDBe PDBsum Gene Ontology AmiGO / EGO [show]Search Botulinum toxin is a protein and neurotoxin produced by the bacterium Clostridium botulinum. Botulinum toxin can cause botulism, a serious and life-threatening illness in humans and animals.[1][2] When introduced intravenously in monkeys, type A (Botox Cosmetic) of the toxin [citation exhibits an LD50 of 40–56 ng, type C1 around 32 ng, type D 3200 ng, and type E 88 ng needed]; these are some of the most potent neurotoxins known.[3] Popularly known by one of its trade names, Botox, it is used for various cosmetic and medical procedures. Botulinum can be absorbed from eyes, mucous membranes, respiratory tract or non-intact skin.[4] Contents [show] [edit] History Justinus Kerner described botulinum toxin as a "sausage poison" and "fatty poison",[5] because the bacterium that produces the toxin often caused poisoning by growing in improperly handled or prepared meat products. It was Kerner, a physician, who first conceived a possible therapeutic use of botulinum toxin and coined the name botulism (from Latin botulus meaning "sausage").
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]